Dr. Petrylak on FDA Approval of Nivolumab in Bladder Cancer

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses the FDA approval of nivolumab (Opdivo) as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy, based on findings from the phase II CheckMate-275 study.

Daniel P. Petrylak, MD, professor of Medicine (Medical Oncology) and Urology, co-director, Signal Transduction Research Program, Yale Cancer Center, discusses the FDA approval of nivolumab (Opdivo) as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy, based on findings from the phase II CheckMate-275 study.

Related Content:

Yale Cancer CenterOncLive TVGenitourinary CancersImmuno-OncologyImmunotherapy in GU Cancers
OncLive’s September Roundup of Key FDA Approvals in Oncology
Dr Saad on the Continued Investigation of Darolutamide Plus ADT in mHSPC
Dr Singhi on Identifying Care Gaps and Unmet Needs in Early-Stage Lung Cancer